All In Biotech

Drug Trial Radar · NCT05615818

Personalized Medicine for Advanced Biliary Cancer Patients

Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Jul 18, 2024

Primary completion

Jun 2027

Study completion Jun 2028

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK & UCL Cancer Trials Centre; Belgian Group of Digestive Oncology; National Cancer Institute, France; Cancer Research UK; Taiho Oncology, Inc.; Servier; Zymeworks BC Inc.; Accord Healthcare, Inc.; Pierre Fabre Medicament
First posted
Nov 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment. The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, during which a molecular profile of the patient's tumour will be obtained, and (ii) a randomised comparative trial in which patients with disease control after 4 cycles of standard treatment, and whose tumour harbours a targetable molecular alteration, will be randomised (2:1) to receive either a matched targeted therapy or to continue with the standard treatment.

Conditions

  • Biliary Tract Neoplasms

Interventions

  • FutibatinibDrug

    Dose 20 mg once a day (QD)

  • IvosidenibDrug

    Dose 500 mg QD

  • ZanidatamabDrug

    Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W

  • TrastuzumabDrug

    Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)

  • NeratinibDrug

    Dose: 240 mg QD (combination with trastuzumab)

  • EncorafenibDrug

    Dose: 450 mg QD (Combination with binimetinib)

  • BinimetinibDrug

    Dose: 45 mg twice a day (BID) (Combination with encorafenib)

  • NiraparibDrug

    Dose: 200 mg QD or 300 mg QD

  • CisplatinDrug

    Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)

  • GemcitabineDrug

    Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From randomisation to disease progression or death, up to 5 years.

Locations

69 sites in 3 countries. Site status is shown where the registry gives one.

  • Cliniques universitaires de Bruxelles - Hôpital Erasme ULB

    Brussels, Belgium · Not yet recruiting

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium · Not yet recruiting

  • Universitair Ziekenhuis Antwerpen (UZA)

    Edegem, Belgium · Not yet recruiting

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium · Not yet recruiting

  • CHU Amiens Picardie

    Amiens, France · Recruiting

  • CHU d'Angers

    Angers, France · Recruiting

  • Institut de cancerologie de l'Ouest - Angers

    Angers, France · Recruiting

  • Institut du Cancer Avignon Provence

    Avignon, France · Recruiting

  • CHU de Besançon

    Besançon, France · Recruiting

  • CHU de Bordeaux - Hôpital Haut-Leveque

    Bordeaux, France · Not yet recruiting

  • Centre François Baclesse

    Caen, France · Recruiting

  • Centre Jean Perrin

    Clermont-Ferrand, France · Recruiting

  • CHU Estaing de Clermont Ferrand

    Clermont-Ferrand, France · Recruiting

  • APHP - Hopital Henri Mondor

    Créteil, France · Recruiting

  • CHU de Dijon

    Dijon, France · Recruiting

  • CHU Grenoble Alpes

    Grenoble, France · Not yet recruiting

  • Groupe hospitalier mutaliste de Grenoble - Institut Daniel Hollard

    Grenoble, France · Recruiting

  • Centre Oscar Lambret

    Lille, France · Recruiting

  • CHU Lille

    Lille, France · Recruiting

  • CHU Dupuytren

    Limoges, France · Recruiting

  • Centre Leon Bérard

    Lyon, France · Not yet recruiting

  • Clinique Privée Jean Mermoz

    Lyon, France · Not yet recruiting

  • Hospices Civils de Lyon - Croix Rousse

    Lyon, France · Recruiting

  • APHM - CHU La Timone

    Marseille, France · Not yet recruiting

  • Hôpital Européen

    Marseille, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • Institut de Cancer de Montpellier

    Montpellier, France · Recruiting

  • CHU Nantes - Hôtel Dieu

    Nantes, France · Not yet recruiting

  • Centre Antoine Lacassagne

    Nice, France · Recruiting

  • APHP - Hôpital Beaujon

    Paris, France · Recruiting

  • APHP - Hôpital Cochin

    Paris, France · Recruiting

  • APHP - Hôpital Saint Antoine

    Paris, France · Recruiting

  • Groupe Hospitalier Diaconesses Croix Saint-Simon

    Paris, France · Not yet recruiting

  • Institute Mutualiste Montsouris

    Paris, France · Recruiting

  • CH de Pau

    Pau, France · Recruiting

  • CHU Poitiers

    Poitiers, France · Recruiting

  • CH Cornouaille

    Quimper, France · Recruiting

  • CHU de Reims

    Reims, France · Recruiting

  • Institut Jean Godinot

    Reims, France · Recruiting

  • Centre Eugène Marquis

    Rennes, France · Recruiting

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.